From Approval to Adoption: A New Framework for Medtech Success

Mercè: Regulatory approval is still a critical milestone in medtech development, but it’s no longer the sole objective. It has become one part of a broader market readiness strategy. While approval validates safety and performance, it doesn’t address key factors like patient relevance, clinician adoption, or payer acceptance. In practice, when development is shaped primarily around regulatory requirements, it can create gaps in evidence and value demonstration that slow adoption and access.

Mercè: We typically see three main challenges emerge from this siloed approach: development delays, low adoption, and delayed access.

Delays often occur when regulatory strategy is disconnected from the expectations of patients, clinicians, and payers—the groups that ultimately determine access, reimbursement, and uptake. That misalignment can lead to device redesigns, extended clinical evaluation, duplicated or misaligned studies, and more complex payer interactions. Questions around device classification, intended use, or evidence requirements can further compound those delays.

Low adoption is another common outcome. When products and studies are designed primarily around regulatory requirements, companies may miss early input from clinicians and patients. Without that insight, it’s harder to define meaningful endpoints or design solutions that reflect real-world use, which ultimately limits uptake.

Finally, if payer engagement comes too late, companies often end up with evidence that supports approval but not coverage. When patient relevance and cost-effectiveness aren’t clearly demonstrated, coverage decisions can be delayed significantly, pushing back market entry and revenue realization. Ultimately, every month of delayed access is a month where patients who could benefit from the device simply don’t have it.

All of these challenges create not just a commercial problem, but a patient access problem.

Mercè: This really highlights a limitation of the traditional, sequential, approval-driven model. To address it, companies need to move toward a more integrated approach. Instead of treating regulatory, clinical, patient engagement, and market access as separate tracks, these elements need to be aligned from the outset.

In practice, that means starting with the patient and speaking with patients. Who are they? What does their care pathway look like? What outcomes matter to them, not just clinically, but in their daily lives? When those answers drive your development plan, regulatory strategy stops being an isolated compliance exercise and becomes part of a coherent story that regulators, clinicians, and payers can all follow.

Mercè: An integrated approach allows you to align claims, endpoints, and value demonstration much earlier, before clinical design is finalized. That’s a critical shift, because it reduces the risk of generating evidence that supports approval but falls short for adoption or coverage.

This approach results in a more efficient development process by limiting rework and allowing teams to identify risks earlier. In practice, this means companies are not only better positioned for regulatory approval, but also for clinician uptake, payer decision-making, and ultimately commercial success.

Mercè: If development is focused primarily on regulatory approval, it can overlook what’s needed for adoption, reimbursement, and value, and that can ultimately undermine commercial success.

A more market-driven approach, where companies build for approval, reimbursement, adoption, and scale in parallel, puts them in a much stronger position. It helps reduce delays, strengthens market access, and increases the likelihood that a product will succeed beyond approval.

In this scenario, regulatory is about more than approval: it’s the strategic backbone of the entire product journey. When you let patient needs drive that strategy from the start, regulatory becomes the force that connects your clinical evidence, your market access pathway, and your commercial reality into one coherent story. You stop building products that get cleared, and start building products that get adopted, reimbursed, and, most importantly, used by the patients who need them.